Business Wire

Ebola Successfully Neutralized by Latest Generation Polyclonal Immunotherapy

Jaa

SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company, today announced that its anti-Ebola immunotherapy (SAB-139) provided “100% protection against a lethal dose of the Ebola virus” in a recent animal study published in The Journal of Infectious Diseases . The study was conducted by the National Interagency Confederation for Biological Research and other collaborators including United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and the Naval Medical Research Center (NMRC).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180815005602/en/

New Ebola immunotherapy developed by SAB Biotherapeutics uses natural human polyclonal antibodies to ...

New Ebola immunotherapy developed by SAB Biotherapeutics uses natural human polyclonal antibodies to combat disease. (Photo: SAB Biotherapeutics)

According to the World Health Organization, Ebola virus disease (EVD), formerly known as Ebola hemorrhagic fever, is a severe, often fatal illness in humans with an average fatality rate around 50%. Case fatality rates have varied from 25% to 90% in past outbreaks, and there is currently no licensed treatment proven to neutralize the virus.

During recent outbreaks of EVD in West Africa, passive immunotherapy with convalescent plasma containing polyclonal antibodies from recovered patients was used as an effective treatment. However, the amount and availability of these medicines are limited by the number of survivors.

SAB-139 was produced from SAB’s proprietary DiversitAb™ platform utilizing transgenic cattle (Tc Bovine™) to produce large amounts of natural human, rather than bovine, antibodies in response to an antigen—in this case EVD.

“This study demonstrates that a human polyclonal antibody-based product can be used to prevent EVD in the most advanced animal model available. This is impressive when one considers that SAB-139 did not require the use of plasma or cells from human EVD survivors,” said Jay Hooper, M.D., chief of the molecular virology branch of USAMRIID. “The ability to rapidly produce a human polyclonal antibody product without the need for material from infected animals or humans could be particularly useful when combating novel emerging infectious diseases.”

In the study, all animals treated with SAB-139 at one-day or three-days post-infection survived versus none of the control animals. In addition, the animals treated with SAB-139 exhibited no symptoms of EVD.

“Polyclonal antibodies are a powerful tool against emerging infectious diseases,” said Eddie J. Sullivan, PhD, SAB Biotherapeutics president and CEO. “They are our body’s natural defense to combat pathogens. With our platform, we can rapidly produce large amounts of targeted human antibodies without using humans—the limiting factor in current convalescent therapies in responding to a widespread outbreak.”

To produce the immunotherapy, Tc Bovine were vaccinated with the EVD antigen. Within a brief period of time, they produced significant amounts of fully human antibodies to combat the virus. Plasma was then collected, in the same way it is collected from human donors, and purified to isolate the antibodies that become the treatment.

“Our DiversitAb platform continues to demonstrate the ability to rapidly produce targeted immunotherapies to emerging infectious diseases with epidemic potential,” added Sullivan. “We will continue to work with our collaborators to develop life-saving medicines for both patients and those who care for them to prevent or stop an outbreak.”

About SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc. (SAB) is a clinical stage biopharmaceutical company leading the science and manufacturing of human antibody therapeutics. Utilizing some of the most advanced polyclonal antibody science, SAB is delivering the world’s first large-scale platform to create fully human immunoglobulins. This natural production platform holds the potential for treatment of public health problems, rare conditions, long-term diseases and global pandemic threats.

Contact information

For SAB Biotherapeutics, Inc.
Melissa Ullerich, +1 605-695-8350
mullerich@sabbiotherapeutics.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Arthur D. Little Appoints Michael Kruse as Head of Global Energy & Utilities Practice23.4.2019 12:42:00 EESTTiedote

Arthur D. Little (ADL) today announced the appointment of Michael Kruse as the new Global Practice Leader for its Global Energy & Utilities practice. A Partner based in ADL’s Frankfurt office, Michael has been with the company for over 11 years, focusing on the strategy and project development behind large-scale capital investment programs in the power sector, including conventional and renewable energies, as well as power grids. His most recent consulting work explored the future of nuclear generation, offshore wind and corporate transformation in the digital era. ADL’s Global Energy and Utilities practice works together with its clients as partners to apply clear thinking to their key strategic issues. It offers a unique ability to combine four factors: a deep, practical understanding of the energy industry and its most difficult challenges, the highest caliber of people, innovation to produce fresh insight, and a commitment to achieving measurable results. Ignacio García Alves, Chai

The New myPOS Go is Here to Become a Market Leader at Just 29 EUR23.4.2019 12:25:00 EESTTiedote

Europe’s fastest growing payments provider, myPOS, today announces the upcoming launch of its latest payment terminal - myPOS Go. Portable and light-weighted, myPOS Go boasts a list of innovative functionalities, emblematic for all myPOS devices – from accepting cards and mobile wallets to sending payment requests and topping up prepaid phones and branded gift cards. At just 29 EUR, merchants will get the new payment device with a free myPOS account and business debit card to it for immediate use of the acquired funds, which are settled instantly after every received payment. The payment terminal is pocket-sized, paperless and perfect for merchants on the go, who seek independence from traditional banks. "Designing payment services with the small and micro businesses in mind, we are aware that some merchants are really sensitive to the cost of payment terminals. Although we do not charge any monthly fees in addition to the device cost, we would like to cater to those merchants and offe

Samsung Sets New Photon Efficacy Level in White LED Packages for Indoor Farms23.4.2019 12:00:00 EESTTiedote

Samsung Electronics Co., Ltd., a world leader in advanced digital component solutions, today announced an industry-leading enhancement to its mid-power LED package – the LM301H – for horticulture applications, such as greenhouse and vertical farming*. At 3.10 micromoles per joule (μmol/J), the newly introduced LM301H now features the highest photon efficacy** among today’s mid-power white LED packages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190423005400/en/ Samsung Horticulture LED LM301H (Photo: Business Wire) “This breakthrough in photon efficacy will go a long way in helping indoor farm owners to maximize plant growth and quality, as well as their profits,” said Un Soo Kim, senior vice president of LED Business Team at Samsung Electronics. “We are committed to continue innovating white LED solutions optimized for healthier plant production as we solidify our leadership in the horticulture lighting industry.” As a

Vivet Therapeutics Announces 2 Abstracts Accepted for Oral Presentation at 2019 American Society of Gene and Cell Therapy Annual Meeting23.4.2019 11:38:00 EESTTiedote

Vivet Therapeutics (“Vivet”), a privately held gene therapy biotech company dedicated to developing gene therapy treatments for inherited liver disorders with high unmet medical need, today announced that new data from its lead development program, VTX-801 a novel investigational gene therapy for WD, and VTX-803, Vivet’ novel therapeutic in development for the treatment of PFIC3, have been accepted for oral presentation during the ASGCT 22nd Annual Meeting, April 29 - May 2, 2019 in Washington, D.C., USA. Dr. Gloria González-Aseguinolaza, Vivet Therapeutics CSO & Head of the Gene Therapy Dept. at FIMA will present data from a recently completed study, validating in WD mice the use of fecal excretion of IV-injected 64copper as a pharmacodynamic endpoint in the VTX-801 Phase I/II trial currently under preparation. These data are the first demonstration of copper homeostasis restoration with 64Copper in an animal model of WD through the delivery of a single, intravenous administration of

Transphorm Centers on the Simplicity and Reliability of High Voltage GaN Application Development at PCIM 201923.4.2019 11:00:00 EESTTiedote

Transphorm Inc.—the leader in the design and manufacturing of the highest reliability and first JEDEC- and AEC-Q101 qualified 650 V and 900 V gallium nitride (GaN) semiconductors—today shared a glimpse into its 2019 PCIM Europe showcase. Located in Hall 9 Booth 519, it centers on three key points to help conference attendees better understand Transphorm’s high voltage GaN value proposition: Reliability: Design with confidence when using Transphorm’s high quality, high reliability (Q+R) GaN transistors. Drivability: Pair Transphorm’s devices with off-the-shelf drivers, for easing drivability. Simplicity: Experience simpler designs due to minimal external gate drive circuitry along with standard packages, such as TO-220, TO-247, and PQFN, with well-known thermal management techniques. “At PCIM, you’ll see the culmination of Transphorm’s innovation along with its measurable impact on low volume as well as high volume customer applications,” said Philip Zuk, Vice President, Technical Marke

PV InfoLink to Host Dialogues with Industry Heavyweights on 2H19 Solar Market Outlook Prior To SNEC23.4.2019 10:00:00 EESTTiedote

A seminar titled “2H19 PV Market Outlook and Forecast” will be held in Shanghai on June 3, one day prior to SNEC, to discuss global supply chain market outlook in the second half of this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190423005391/en/ 2019 Module Prices and Demand Forecast. (Photo: Business Wire) Held by PV InfoLink, a leading solar market intelligence provider, the seminar will bring together PV manufacturers, developers, EPC, and investors to explore major issues revolving the industry and help participants gain valuable insights for navigating the expanding solar market. PV InfoLink has invited Chinese major companies, including Jinko, Longi, and GCL-Si, to discuss impact of China’s transition to a subsidy-free market. This year, China’s demand will revive later than usual due to policy uncertainty. Moreover, Japan and India, China’s two major trading partners, saw weakening demand after the end of f

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme